US2002064848A1PendingUtilityA1

Novel histidinol dehydrogenase

59
Priority: Sep 24, 1996Filed: Mar 14, 2001Published: May 30, 2002
Est. expirySep 24, 2016(expired)· nominal 20-yr term from priority
Inventors:Michael Terence BlackJohn Edward HodgsonDavid Justin Charles KnowlesRaymond Winfield ReichardRichard Oakley NicholasMartin Karl Russel BurnhamJulie M PrattMartin RosenbergJudith M WardMichael Arthur LonettoPatrick Vernon Warren
C12N 9/00A61P 35/00C07K 2319/00A61K 38/00C07K 14/31Y10S435/883A61P 43/00C12N 9/88A61P 37/04A61P 31/04C12N 9/1205A61P 37/00C12N 9/0006A61K 39/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides histidinol dehydrogenase polypeptides and DNA (RNA) encoding histidinol dehydrogenase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing histidinol dehydrogenase polypeptides to screen for antibacterial compounds.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 50 consecutive amino acids of SEQ ID NO:2 ; wherein said fragment has histidinol dehydrogenase activity.  
     
     
         2 . A composition comprising the isolated polypeptide of  claim 1  and a carrier.  
     
     
         3 . The isolated polypeptide of  claim 1 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2.  
     
     
         4 . A composition comprising the isolated polypeptide of  claim 3  and a carrier.  
     
     
         5 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 30 consecutive amino acids of SEQ ID NO:2; wherein said fragment has histidinol dehydrogenase activity.  
     
     
         6 . A composition comprising the isolated polypeptide of  claim 5  and a carrier.  
     
     
         7 . The isolated polypeptide of  claim 5 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2.  
     
     
         8 . A composition comprising the isolated polypeptide of  claim 7  and a carrier.  
     
     
         9 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 50 consecutive amino acids of SEQ ID NO:2; wherein said fragment has the ability to generate antibodies to SEQ ID NO:2.  
     
     
         10 . A composition comprising the isolated polypeptide of  claim 9  and a carrier.  
     
     
         11 . The isolated polypeptide of  claim 9 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2.  
     
     
         12 . A composition comprising the isolated polypeptide of  claim 11  and a carrier.  
     
     
         13 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 30 consecutive amino acids of SEQ ID NO:2; wherein said fragment has the ability to generate antibodies to SEQ ID NO:2.  
     
     
         14 . A composition comprising the isolated polypeptide of  claim 13  and a carrier.  
     
     
         15 . The isolated polypeptide of  claim 13 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2.  
     
     
         16 . A composition comprising the isolated polypeptide of  claim 15  and a carrier.

Join the waitlist — get patent alerts

Track US2002064848A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.